InflaRx (IFRX) has released an update.
InflaRx has showcased the potential of its new drug INF904, targeting chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), with Phase 2a trials to start by end of 2024 and results expected by summer 2025. The drug could address a multi-billion-dollar market opportunity for these conditions. The company’s robust financial position is expected to fund operations into 2026, supporting the advancement of its clinical programs.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.
